Riboflavin-Responsive Multiple Acyl-CoA Dehydrogenase Deficiency Associated with Hepatoencephalomyopathy and White Matter Signal Abnormalities on Brain MRI

Abstract

Multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare inborn error of metabolism affecting both fatty acid and amino acid oxidation. It can manifest at any age, but riboflavin-responsiveness has mainly been described in less severely affected patients. We describe an infant with severe MADD presenting with profound hypotonia and hepatomegaly. Treatment with riboflavin improved his muscle strength, liver size, and biochemical markers. A homozygous mutation of electron transfer flavoprotein dehydrogenase (ETFDH) was found. His motor skills continued to progress until a fatal infection-triggered deterioration at the age of 34 months. We show changes in brain magnetic resonance imaging over the course of the disease, with profound white matter abnormalities during the deterioration phase. Aggregates of mitochondria with abnormal cristae in muscle electron microscopy were noticed already in infancy. An unusual lactate dehydrogenase (LDH) isoenzyme pattern with LDH-1 predominance was additionally observed. This case demonstrates riboflavin-responsiveness in a severely affected infant with both muscular and extramuscular involvement and further underlines the variable nature of this disease.

Keywords

MADD - glutaric aciduria type 2 - ETFDH - infant

^* The authors Drs. Myllynen and Perhomaa contributed equally to this work.

• References

• 1 Olsen RK, Olpin SE, Andresen BS , et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 2007; 130 (Pt 8): 2045-2054
• 2 Xi J, Wen B, Lin J , et al. Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2014; 37 (3) 399-404
• 3 Zhu M, Zhu X, Qi X , et al. Riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency in 13 cases, and a literature review in mainland Chinese patients. J Hum Genet 2014; 59 (5) 256-261
• 4 Olsen RK, Andresen BS, Christensen E, Bross P, Skovby F, Gregersen N. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat 2003; 22 (1) 12-23
• 5 Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban C. Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab 2006; 88 (2) 153-158
• 6 Wilson GN, de Chadarévian JP, Kaplan P, Loehr JP, Frerman FE, Goodman SI. Glutaric aciduria type II: review of the phenotype and report of an unusual glomerulopathy. Am J Med Genet 1989; 32 (3) 395-401
• 7 al-Essa MA, Rashed MS, Bakheet SM, Patay ZJ, Ozand PT. Glutaric aciduria type II: observations in seven patients with neonatal- and late-onset disease. J Perinatol 2000; 20 (2) 120-128
• 8 Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008; 93 (1) 36-39
• 9 Henriques BJ, Rodrigues JV, Olsen RK, Bross P, Gomes CM. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. J Biol Chem 2009; 284 (7) 4222-4229
• 10 Béhin A, Acquaviva-Bourdain C, Souvannanorath S , et al. Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of late-onset treatable metabolic disease. Rev Neurol (Paris) 2016; 172 (3) 231-241
• 11 Olsen RK, Koňaříková E, Giancaspero TA , et al. Riboflavin-responsive and non-responsive mutations in FAD synthase cause multiple acyl-CoA dehydrogenase and combined respiratory-chain deficiency. Am J Hum Genet 2016; 98 (6) 1130-1145
• 12 Van Hove JL, Grünewald S, Jaeken J , et al. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 2003; 361 (9367): 1433-1435
• 13 Van Rijt WJ, Heiner-Fokkema MR, du Marchie Sarvaas GJ , et al. Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD. Pediatrics 2014; 134 (4) e1224-e1228
• 14 Therrell BL, Padilla CD, Loeber JG , et al. Current status of newborn screening worldwide: 2015. Semin Perinatol 2015; 39 (3) 171-187
• 15 Kim SH, Scott SA, Bennett MJ , et al. Multi-organ abnormalities and mTORC1 activation in zebrafish model of multiple acyl-CoA dehydrogenase deficiency. PLoS Genet 2013; 9 (6) e1003563
• 16 Sugai F, Baba K, Toyooka K , et al. Adult-onset multiple acyl CoA dehydrogenation deficiency associated with an abnormal isoenzyme pattern of serum lactate dehydrogenase. Neuromuscul Disord 2012; 22 (2) 159-161
• 17 Shevell MI, Didomenicantonio G, Sylvain M, Arnold DL, O'Gorman AM, Scriver CR. Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy. Pediatr Neurol 1995; 12 (4) 350-353
• 18 Takanashi J, Fujii K, Sugita K, Kohno Y. Neuroradiologic findings in glutaric aciduria type II. Pediatr Neurol 1999; 20 (2) 142-145
• 19 Firat AK, Karakas HM, Yakinci C. Magnetic resonance spectroscopic characteristics of glutaric aciduria type II. Dev Med Child Neurol 2006; 48 (10) 847-850
• 20 Mumtaz HA, Gupta V, Singh P, Marwaha RK, Khandelwal N. MR imaging findings of glutaric aciduria type II. Singapore Med J 2010; 51 (4) e69-e71
• 21 Gautschi M, Weisstanner C, Slotboom J, Nava E, Zürcher T, Nuoffer JM. Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy. Pediatr Res 2015; 77 (1-1): 91-98